QURE News and Press, uniQure N.V. From 03/02/26

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.2% to $1.83 on volume of 883,419,339 shares Trio Petroleum Corp. (TPET) rose 157.5% to $1.0816 on volume of 411,497,833 shares Ondas Inc (ONDS) rose 2.6% to $10.34 on volume of 1...

2026-03-02 13:03:38 ET Paul Matteis from Stifel Nicolaus issued a price target of $14.00 for QURE on 2026-03-02 16:23:00. The adjusted price target was set to $14.00. At the time of the announcement, QURE was trading at $10.3. The overall price target consensus is at $53...

2026-03-02 13:03:38 ET Luca Issi from RBC Capital issued a price target of $11.00 for QURE on 2026-03-02 16:33:00. The adjusted price target was set to $11.00. At the time of the announcement, QURE was trading at $10.25. The overall price target consensus is at $53.89 wi...

2026-03-02 12:15:06 ET Cantor Fitzgerald analyst issues NEUTRAL recommendation for QURE on March 2, 2026 03:14PM ET. The previous analyst recommendation was Overweight. QURE was trading at $10.045 at issue of the analyst recommendation. The overall analyst consensus : BU...

2026-03-02 09:47:11 ET Image source: The Motley Fool. March 2, 2026, 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-02 07:13:07 ET More on uniQure uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know uniQure: Now What? uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump uniQure falls after FDA commissioner’s comments on ...

~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-2...

Astrana Health Inc. (ASTH) is expected to report $0.15 for Q4 2025 Sealed Air Corporation (SEE) is expected to report $0.72 for Q4 2025 Surgery Partners Inc. (SGRY) is expected to report $0.27 for Q4 2025 Kuehne + Nagel International AG ADR (KHNGY) is expected to report $0.4 for Q4 20...

2026-02-27 10:49:58 ET Investment Overview Shares of the Amsterdam, Netherlands based gene therapy specialist drug developer uniQure N.V. ( QURE ) were in freefall yesterday, dropping by >30% as the market digested comments made by FDA commissioner Dr Marty Makary during ...

2026-02-27 10:47:32 ET More on uniQure uniQure: Now What? uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump uniQure falls after FDA commissioner’s comments on rare disease therapy uniQure gains as FDA sets up meeting on gene therapy ...